Actemra 400mg is a recombinant humanized anti-human interleukin 6 (IL-6) receptor monoclonal antibody of the immunoglobulin (gamma 1, kappa) subclass with a typical H2L2 polypeptide structure. Also, Each light chain and heavy chain consists of 214 and 448 amino acids, respectively. The four polypeptide chains are linked intra- and inter-molecularly by disulfide bonds. Actemra has a molecular weight of approximately 148 kDa.
Actemra 400mg is supplied as a sterile, preservative-free solution for intravenous (IV) infusion at a concentration of 20 mg per mL.
Actemra is a colorless to pale yellow liquid, with a pH of about 6.5. Single-use vials are available for intravenous administration containing 80 mg per 4 mL, 200 mg per 10 mL, or 400 mg per 20 Ml of Actemra. Injectable solutions of Actemra 400mg are formulated in an aqueous solution containing disodium phosphate dodecahydrate and sodium dihydrogen phosphate dehydrate (as a 15 mmol per L phosphate buffer), polysorbate 80 (0.5 mg per mL), and sucrose (50 mg per mL).
Actemra 400mg is a solution for subcutaneous administration is supplied as a sterile, colorless to yellowish, preservative-free liquid solution of approximately pH 6.0. It is supplied in a 1 mL ready-to-use, a single-use prefilled syringe (PFS) with a needle safety device. Each device delivers 0.9 mL (162 mg) of Acterma, in a histidine buffered solution composed of Actemra (180 mg/mL), polysorbate 80, L-histidine and L-histidine monohydrochloride, L-arginine and L-arginine hydrochloride, L-methionine, and water for injection.